AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. ESGR
  4. [S-8 POS] Enstar Group SEC Filing

[S-8 POS] Enstar Group SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
S-8 POS
Rhea-AI Filing Summary

Form 4 overview: Director John Paulson reported a routine equity grant from Bausch Health Companies Inc. (NYSE: BHC) dated 06/30/2025.

  • Transaction: 9,384 restricted share units (RSUs) issued in lieu of quarterly cash board fees; coded 鈥淎鈥� (acquired) at a cost basis of $0.
  • Direct holdings: Increase to 341,439 common shares after the grant.
  • Indirect holdings: Paulson-managed funds continue to own 32,791,702 shares; Paulson disclaims beneficial ownership beyond his pecuniary interest.
  • Nature of grant: RSUs convert 1-for-1 into common shares at vesting, further aligning the director鈥檚 incentives with shareholders but creating negligible dilution given BHC鈥檚 ~365 million shares outstanding.

No cash was exchanged and there were no derivative transactions. The filing reflects standard board compensation rather than an active investment decision, so immediate market impact is expected to be minimal.

Panoramica del Modulo 4: Il direttore John Paulson ha dichiarato una normale assegnazione di azioni da Bausch Health Companies Inc. (NYSE: BHC) datata 30/06/2025.

  • Transazione: 9.384 unit脿 azionarie vincolate (RSU) emesse in sostituzione delle commissioni trimestrali in contanti del consiglio; codificate come 鈥淎鈥� (acquisite) con un costo base di 0$.
  • Detenzioni dirette: Aumento a 341.439 azioni ordinarie dopo l鈥檃ssegnazione.
  • Detenzioni indirette: I fondi gestiti da Paulson continuano a detenere 32.791.702 azioni; Paulson nega la titolarit脿 effettiva oltre il suo interesse economico.
  • Natura dell鈥檃ssegnazione: Le RSU si convertono 1 a 1 in azioni ordinarie al momento del vesting, allineando ulteriormente gli incentivi del direttore con quelli degli azionisti, ma generando una diluizione trascurabile dato il totale di circa 365 milioni di azioni BHC in circolazione.

Non 猫 stato scambiato denaro n茅 effettuate transazioni su derivati. La dichiarazione riflette una normale remunerazione del consiglio piuttosto che una decisione di investimento attiva, quindi l鈥檌mpatto immediato sul mercato 猫 previsto minimo.

Resumen del Formulario 4: El director John Paulson report贸 una concesi贸n rutinaria de acciones de Bausch Health Companies Inc. (NYSE: BHC) con fecha 30/06/2025.

  • 罢谤补苍蝉补肠肠颈贸苍: 9,384 unidades restringidas de acciones (RSUs) emitidas en lugar de las tarifas trimestrales en efectivo del consejo; codificadas como 鈥淎鈥� (adquiridas) con un costo base de $0.
  • Participaciones directas: Aumento a 341,439 acciones ordinarias tras la concesi贸n.
  • Participaciones indirectas: Los fondos gestionados por Paulson contin煤an poseyendo 32,791,702 acciones; Paulson niega la propiedad beneficiaria m谩s all谩 de su inter茅s econ贸mico.
  • Naturaleza de la concesi贸n: Las RSUs se convierten 1 a 1 en acciones ordinarias al consolidarse, alineando a煤n m谩s los incentivos del director con los accionistas, pero generando una diluci贸n m铆nima dado el total de aproximadamente 365 millones de acciones en circulaci贸n de BHC.

No se intercambi贸 efectivo ni hubo transacciones con derivados. La presentaci贸n refleja una compensaci贸n est谩ndar de la junta m谩s que una decisi贸n activa de inversi贸n, por lo que se espera un impacto inmediato en el mercado m铆nimo.

Form 4 臧滌殧: 鞚挫偓 John Paulson鞚� Bausch Health Companies Inc. (NYSE: BHC)搿滊秬韯� 2025雲� 6鞗� 30鞚检瀽 鞝曣赴 欤检嫕 攵�鞐ゼ 氤搓碃頄堨姷雼堧嫟.

  • 瓯半灅 雮挫毄: 攵勱赴 順勱笀 鞚挫偓須� 靾橃垬耄� 雽�鞁� 氚滍枆霅� 9,384臧滌潣 鞝滍暅 欤检嫕 雼渼(RSU); 牍勳毄 旮办 $0搿� 鈥淎鈥�(旆摑) 旖旊摐 觳橂Μ霅�.
  • 歆侅爲 氤挫湢: 攵�鞐� 頉� 341,439 氤错喌欤�搿� 歃濌皜.
  • 臧勳爲 氤挫湢: Paulson鞚� 甏�毽晿電� 韼�霌滊姅 瓿勳啀頃挫劀 32,791,702欤�毳� 氤挫湢 欷戩澊氅�, Paulson鞚� 鞛愳嫚鞚� 旮堨爠鞝� 鞚挫澋鞚� 雱橃柎靹� 鞁れ鞝� 靻岇湢甓岇潉 攵�鞚疙暕雼堧嫟.
  • 攵�鞐潣 靹标博: RSU電� 氩犾姢韺� 鞁� 1雽�1搿� 氤错喌欤茧 鞝勴櫂霅橃柎 鞚挫偓鞚� 鞚胳劶韹半笇毳� 欤检＜鞕� 雿旍毐 鞚检箻鞁滍偆歆�毵�, BHC鞚� 鞎� 3鞏� 6,500毵� 欤� 氚滍枆 欤检嫕 靾橂ゼ 瓿犽牑頃� 霑� 頋劃 須臣電� 氙鸽頃╇媹雼�.

順勱笀 甑愴櫂鞚措倶 韺岇儩靸來拡 瓯半灅電� 鞐嗢棃鞀惦媹雼�. 鞚� 鞁犼碃電� 鞝侁饭鞝侅澑 韴瀽 瓴办爼鞚� 鞎勲媽 響滌 鞚挫偓須� 氤挫儊鞚� 氚橃榿頃橂瘈搿� 歃夑皝鞝侅澑 鞁滌灔 鞓來枼鞚� 氙鸽頃� 瓴冹溂搿� 鞓堨儊霅╇媹雼�.

Pr茅sentation du formulaire 4 : Le directeur John Paulson a d茅clar茅 une attribution r茅guli猫re d鈥檃ctions de Bausch Health Companies Inc. (NYSE : BHC) dat茅e du 30/06/2025.

  • Transaction : 9 384 unit茅s d鈥檃ctions restreintes (RSU) 茅mises en remplacement des frais trimestriels en esp猫ces du conseil ; cod茅es 芦 A 禄 (acquises) avec un co没t de base de 0 $.
  • D茅tentions directes : Augmentation 脿 341 439 actions ordinaires apr猫s l鈥檃ttribution.
  • D茅tentions indirectes : Les fonds g茅r茅s par Paulson poss猫dent toujours 32 791 702 actions ; Paulson nie toute propri茅t茅 b茅n茅ficiaire au-del脿 de son int茅r锚t p茅cuniaire.
  • Nature de l鈥檃ttribution : Les RSU se convertissent en actions ordinaires 脿 raison de 1 pour 1 lors de la lev茅e des restrictions, alignant davantage les incitations du directeur avec celles des actionnaires, tout en cr茅ant une dilution n茅gligeable compte tenu des quelque 365 millions d鈥檃ctions BHC en circulation.

Aucun 茅change d鈥檃rgent liquide ni transaction sur d茅riv茅s n鈥檃 eu lieu. Le d茅p么t refl猫te une r茅mun茅ration standard du conseil d鈥檃dministration plut么t qu鈥檜ne d茅cision d鈥檌nvestissement active, de sorte que l鈥檌mpact imm茅diat sur le march茅 devrait 锚tre minime.

脺berblick Formular 4: Direktor John Paulson meldete eine routinem盲脽ige Aktienzuteilung von Bausch Health Companies Inc. (NYSE: BHC) datiert auf den 30.06.2025.

  • Transaktion: 9.384 beschr盲nkte Aktieneinheiten (RSUs), ausgegeben anstelle der viertelj盲hrlichen Barverg眉tungen des Vorstands; als 鈥濧鈥� (erworben) mit einem Kostenbasis von 0$ codiert.
  • Direkte Beteiligungen: Erh枚hung auf 341.439 Stammaktien nach der Zuteilung.
  • Indirekte Beteiligungen: Von Paulson verwaltete Fonds halten weiterhin 32.791.702 Aktien; Paulson bestreitet wirtschaftliches Eigentum 眉ber sein finanzielles Interesse hinaus.
  • Art der Zuteilung: RSUs wandeln sich beim Vesting 1:1 in Stammaktien um, was die Anreize des Direktors st盲rker mit denen der Aktion盲re in Einklang bringt, jedoch bei ca. 365 Millionen ausstehenden BHC-Aktien eine vernachl盲ssigbare Verw盲sserung bedeutet.

Es wurde kein Bargeld ausgetauscht und keine Derivatgesch盲fte get盲tigt. Die Meldung spiegelt eine standardm盲脽ige Vorstandsverg眉tung wider und keine aktive Investitionsentscheidung, daher wird ein unmittelbarer Markteinfluss als gering eingesch盲tzt.

Positive
  • Director-shareholder alignment strengthens as John Paulson accepts equity rather than cash fees.
Negative
  • None.

Insights

TL;DR: Routine RSU grant; alignment positive, impact immaterial.

The RSU grant is standard compensation for Bausch Health directors. While it modestly raises Paulson鈥檚 direct stake, the 9.4k-share addition is immaterial relative to the 32.8 million shares his funds already control. The disclosure confirms continued board participation and no change in control dynamics. Given BHC鈥檚 large float, dilution is statistically insignificant. I view the filing as governance-neutral with a slight positive signal of ongoing alignment.

TL;DR: No trading signal; holdings unchanged in substance.

From a portfolio standpoint, this Form 4 does not alter BHC鈥檚 investment thesis. The RSUs reflect compensation, not a discretionary purchase, and carry a zero cost basis. Paulson鈥檚 significant indirect stake鈥攔oughly 9% of outstanding shares鈥攔emains intact, so ownership concentration is unchanged. Liquidity, earnings outlook, and debt reduction efforts remain primary drivers; today鈥檚 disclosure is operationally and financially non-impactful.

Panoramica del Modulo 4: Il direttore John Paulson ha dichiarato una normale assegnazione di azioni da Bausch Health Companies Inc. (NYSE: BHC) datata 30/06/2025.

  • Transazione: 9.384 unit脿 azionarie vincolate (RSU) emesse in sostituzione delle commissioni trimestrali in contanti del consiglio; codificate come 鈥淎鈥� (acquisite) con un costo base di 0$.
  • Detenzioni dirette: Aumento a 341.439 azioni ordinarie dopo l鈥檃ssegnazione.
  • Detenzioni indirette: I fondi gestiti da Paulson continuano a detenere 32.791.702 azioni; Paulson nega la titolarit脿 effettiva oltre il suo interesse economico.
  • Natura dell鈥檃ssegnazione: Le RSU si convertono 1 a 1 in azioni ordinarie al momento del vesting, allineando ulteriormente gli incentivi del direttore con quelli degli azionisti, ma generando una diluizione trascurabile dato il totale di circa 365 milioni di azioni BHC in circolazione.

Non 猫 stato scambiato denaro n茅 effettuate transazioni su derivati. La dichiarazione riflette una normale remunerazione del consiglio piuttosto che una decisione di investimento attiva, quindi l鈥檌mpatto immediato sul mercato 猫 previsto minimo.

Resumen del Formulario 4: El director John Paulson report贸 una concesi贸n rutinaria de acciones de Bausch Health Companies Inc. (NYSE: BHC) con fecha 30/06/2025.

  • 罢谤补苍蝉补肠肠颈贸苍: 9,384 unidades restringidas de acciones (RSUs) emitidas en lugar de las tarifas trimestrales en efectivo del consejo; codificadas como 鈥淎鈥� (adquiridas) con un costo base de $0.
  • Participaciones directas: Aumento a 341,439 acciones ordinarias tras la concesi贸n.
  • Participaciones indirectas: Los fondos gestionados por Paulson contin煤an poseyendo 32,791,702 acciones; Paulson niega la propiedad beneficiaria m谩s all谩 de su inter茅s econ贸mico.
  • Naturaleza de la concesi贸n: Las RSUs se convierten 1 a 1 en acciones ordinarias al consolidarse, alineando a煤n m谩s los incentivos del director con los accionistas, pero generando una diluci贸n m铆nima dado el total de aproximadamente 365 millones de acciones en circulaci贸n de BHC.

No se intercambi贸 efectivo ni hubo transacciones con derivados. La presentaci贸n refleja una compensaci贸n est谩ndar de la junta m谩s que una decisi贸n activa de inversi贸n, por lo que se espera un impacto inmediato en el mercado m铆nimo.

Form 4 臧滌殧: 鞚挫偓 John Paulson鞚� Bausch Health Companies Inc. (NYSE: BHC)搿滊秬韯� 2025雲� 6鞗� 30鞚检瀽 鞝曣赴 欤检嫕 攵�鞐ゼ 氤搓碃頄堨姷雼堧嫟.

  • 瓯半灅 雮挫毄: 攵勱赴 順勱笀 鞚挫偓須� 靾橃垬耄� 雽�鞁� 氚滍枆霅� 9,384臧滌潣 鞝滍暅 欤检嫕 雼渼(RSU); 牍勳毄 旮办 $0搿� 鈥淎鈥�(旆摑) 旖旊摐 觳橂Μ霅�.
  • 歆侅爲 氤挫湢: 攵�鞐� 頉� 341,439 氤错喌欤�搿� 歃濌皜.
  • 臧勳爲 氤挫湢: Paulson鞚� 甏�毽晿電� 韼�霌滊姅 瓿勳啀頃挫劀 32,791,702欤�毳� 氤挫湢 欷戩澊氅�, Paulson鞚� 鞛愳嫚鞚� 旮堨爠鞝� 鞚挫澋鞚� 雱橃柎靹� 鞁れ鞝� 靻岇湢甓岇潉 攵�鞚疙暕雼堧嫟.
  • 攵�鞐潣 靹标博: RSU電� 氩犾姢韺� 鞁� 1雽�1搿� 氤错喌欤茧 鞝勴櫂霅橃柎 鞚挫偓鞚� 鞚胳劶韹半笇毳� 欤检＜鞕� 雿旍毐 鞚检箻鞁滍偆歆�毵�, BHC鞚� 鞎� 3鞏� 6,500毵� 欤� 氚滍枆 欤检嫕 靾橂ゼ 瓿犽牑頃� 霑� 頋劃 須臣電� 氙鸽頃╇媹雼�.

順勱笀 甑愴櫂鞚措倶 韺岇儩靸來拡 瓯半灅電� 鞐嗢棃鞀惦媹雼�. 鞚� 鞁犼碃電� 鞝侁饭鞝侅澑 韴瀽 瓴办爼鞚� 鞎勲媽 響滌 鞚挫偓須� 氤挫儊鞚� 氚橃榿頃橂瘈搿� 歃夑皝鞝侅澑 鞁滌灔 鞓來枼鞚� 氙鸽頃� 瓴冹溂搿� 鞓堨儊霅╇媹雼�.

Pr茅sentation du formulaire 4 : Le directeur John Paulson a d茅clar茅 une attribution r茅guli猫re d鈥檃ctions de Bausch Health Companies Inc. (NYSE : BHC) dat茅e du 30/06/2025.

  • Transaction : 9 384 unit茅s d鈥檃ctions restreintes (RSU) 茅mises en remplacement des frais trimestriels en esp猫ces du conseil ; cod茅es 芦 A 禄 (acquises) avec un co没t de base de 0 $.
  • D茅tentions directes : Augmentation 脿 341 439 actions ordinaires apr猫s l鈥檃ttribution.
  • D茅tentions indirectes : Les fonds g茅r茅s par Paulson poss猫dent toujours 32 791 702 actions ; Paulson nie toute propri茅t茅 b茅n茅ficiaire au-del脿 de son int茅r锚t p茅cuniaire.
  • Nature de l鈥檃ttribution : Les RSU se convertissent en actions ordinaires 脿 raison de 1 pour 1 lors de la lev茅e des restrictions, alignant davantage les incitations du directeur avec celles des actionnaires, tout en cr茅ant une dilution n茅gligeable compte tenu des quelque 365 millions d鈥檃ctions BHC en circulation.

Aucun 茅change d鈥檃rgent liquide ni transaction sur d茅riv茅s n鈥檃 eu lieu. Le d茅p么t refl猫te une r茅mun茅ration standard du conseil d鈥檃dministration plut么t qu鈥檜ne d茅cision d鈥檌nvestissement active, de sorte que l鈥檌mpact imm茅diat sur le march茅 devrait 锚tre minime.

脺berblick Formular 4: Direktor John Paulson meldete eine routinem盲脽ige Aktienzuteilung von Bausch Health Companies Inc. (NYSE: BHC) datiert auf den 30.06.2025.

  • Transaktion: 9.384 beschr盲nkte Aktieneinheiten (RSUs), ausgegeben anstelle der viertelj盲hrlichen Barverg眉tungen des Vorstands; als 鈥濧鈥� (erworben) mit einem Kostenbasis von 0$ codiert.
  • Direkte Beteiligungen: Erh枚hung auf 341.439 Stammaktien nach der Zuteilung.
  • Indirekte Beteiligungen: Von Paulson verwaltete Fonds halten weiterhin 32.791.702 Aktien; Paulson bestreitet wirtschaftliches Eigentum 眉ber sein finanzielles Interesse hinaus.
  • Art der Zuteilung: RSUs wandeln sich beim Vesting 1:1 in Stammaktien um, was die Anreize des Direktors st盲rker mit denen der Aktion盲re in Einklang bringt, jedoch bei ca. 365 Millionen ausstehenden BHC-Aktien eine vernachl盲ssigbare Verw盲sserung bedeutet.

Es wurde kein Bargeld ausgetauscht und keine Derivatgesch盲fte get盲tigt. Die Meldung spiegelt eine standardm盲脽ige Vorstandsverg眉tung wider und keine aktive Investitionsentscheidung, daher wird ein unmittelbarer Markteinfluss als gering eingesch盲tzt.

 

As filed with the Securities and Exchange Commission on July 2, 2025

 

Registration Statement No. 333-141793

Registration Statement No. 333-148862

Registration Statement No. 333-148863

Registration Statement No. 333-149551

Registration Statement No. 333-212131

Registration Statement No. 333-237259

Registration Statement No. 333-265567

 

 

  

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-141793

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-148862

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-148863

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-149551

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-212131

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-237259

POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-265567

 

 

UNDER

THE SECURITIES ACT OF 1933

 

  

ENSTAR GROUP LIMITED

(Exact name of registrant as specified in its charter)

 

   

Bermuda   N/A

(State or other jurisdiction of

incorporation or organization)

  

(IRS Employer

Identification No.)

 

A.S. Cooper Building, 4th Floor, 26 Reid Street

Hamilton HM 11, Bermuda

(Address of Principal Executive Offices)

 

  

Enstar Group Limited 2006 Equity Incentive Plan
(formerly the Castlewood Holdings Limited 2006 Equity Incentive Plan)

The Enstar Group, Inc. 1997 Omnibus Incentive Plan
The Enstar Group, Inc. 2001 Outside Directors Stock Option Plan

Enstar Group Limited Deferred Compensation and Ordinary Share Plan for Non-Employee Directors

Enstar Group Limited Employee Share Purchase Plan

Enstar Group Limited 2016 Equity Incentive Plan

Enstar Group Limited Amended and Restated 2016 Equity Incentive Plan

(Full title of the plans)

 

  

Enstar (US) Inc.

55 West 46th Street, Suite 2805

New York, NY 10036

(212) 790-9700

(Name, address and telephone number, including area code, of agent for service)

 

Copies of all communications, including communications sent to agent for service, should be sent to:

 

Katherine M. Krause

Xiaohui (Hui) Lin

Louis H. Argentieri

Simpson Thacher & Bartlett LLP

425 Lexington Avenue

New York, New York 10017

(212) 455-2000

Enstar Group Limited

A.S. Cooper Building, 4th Floor, 26 Reid Street

Hamilton HM 11, Bermuda

(441) 292-3645

 

  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer x   Accelerated filer ¨
       
Non-accelerated filer ¨   Smaller reporting company ¨
       
      Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

 

 

 

 

EXPLANATORY NOTE

 

Enstar Global Limited, an exempted company limited by shares existing under the laws of Bermuda (the “Company”, “Enstar”, or the “Registrant”), is filing with the Securities and Exchange Commission (the “Commission”) these post-effective amendments (these “Post-Effective Amendments”) to deregister any and all securities previously registered under the following Registration Statements on Form S-8 (the “Registration Statements”) that remain unsold or otherwise unissued under each such Registration Statement as of the date hereof (note that the share numbers listed below do not take into account corporate actions taken in the interim):

 

·Registration Statement No. 333-141793 filed with the Commission on April 2, 2007, registering 1,200,000 ordinary shares issuable pursuant to the Enstar Group Limited 2006 Equity Incentive Plan;
·Registration Statement No. 333-148862 filed with the Commission on January 25, 2008, registering 460,949 ordinary shares issuable pursuant to The Enstar Group, Inc. 1997 Omnibus Incentive Plan and 29,422 ordinary shares issuable pursuant to The Enstar Group, Inc. 2001 Outside Director’s Stock Option Plan;
·Registration Statement No. 333-148863 filed with the Commission on January 25, 2008, registering 97,862 ordinary shares issuable pursuant to the Enstar Group Limited Deferred Compensation Plan for Non-Employee Directors;
·Registration Statement No. 333-149551 filed with the Commission on March 5, 2008, registering 200,000 ordinary shares issuable pursuant to the Enstar Group Limited Employee Share Purchase Plan;
·Registration Statement No. 333-212131 filed with the Commission on June 20, 2016, registering 689,654 ordinary shares issuable pursuant to the Enstar Group Limited 2016 Equity Incentive Plan;
·Registration Statement No. 333-237259 filed with the Commission on March 18, 2020, registering 84,370 ordinary shares issuable pursuant to the Enstar Group Limited Amended and Restated 2016 Equity Incentive Plan;
·Registration Statement No. 333-265567 filed with the Commission on June 14, 2022, registering 400,000 ordinary shares issuable pursuant to the Enstar Group Limited Amended and Restated 2016 Equity Incentive Plan.

 

On July 2, 2025, pursuant to the Agreement and Plan of Merger dated as of July 29, 2024, by and among Enstar, Elk Bidco Limited, an exempted company limited by shares existing under the laws of Bermuda (“Parent”), Elk Merger Sub Limited, an exempted company limited by shares existing under the laws of Bermuda and a directly wholly owned subsidiary of Parent, Deer Ltd., an exempted company limited by shares existing under the laws of Bermuda and a direct wholly owned subsidiary of the Company, and Deer Merger Sub Ltd., an exempted company limited by shares existing under the laws of Bermuda and a direct wholly owned subsidiary of Deer Ltd., the parties effected a series of mergers (collectively, the “Mergers”), with Enstar surviving the Mergers as a wholly owned subsidiary of Parent. These Post-Effective Amendments are being filed as a result of the Mergers.

 

The Company, by filing these Post-Effective Amendments, hereby terminates the effectiveness of the Registration Statements and removes from registration any and all securities registered but unsold or otherwise unissued under the Registration Statements as of the date hereof. These filings are made in accordance with an undertaking made by the Company in Part II of each Registration Statement to remove from registration, by means of a post-effective amendment, any securities that had been registered for issuance but remain unsold at the termination of the offering.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Hamilton, Bermuda on July 2, 2025.

 

  ENSTAR GROUP LIMITED
   
  By: /s/ Audrey B. Taranto
  Name: Audrey B. Taranto
  Title: General Counsel

 

Pursuant to Rule 478 under the Securities Act of 1933, as amended, no other person is required to sign these Post-Effective Amendments to the Registration Statements.

 

 

 

Source:

FAQ

How many BHC shares did John Paulson acquire on 06/30/2025?

He received 9,384 restricted share units, each convertible into one common share.

What is John Paulson鈥檚 total beneficial ownership in BHC after the transaction?

Directly 341,439 shares; indirectly, funds he manages hold 32,791,702 shares.

Did John Paulson pay for the shares?

No. The RSUs were granted at $0 cost as board compensation for the quarter ending 06/30/2025.

Does this Form 4 signal insider buying of BHC stock?

Not materially. The grant is routine compensation, not an open-market purchase.

When was the Form 4 for Bausch Health filed?

The filing was signed and dated 07/02/2025.
Stock ESGR logo
Enstar Group Limited

NASDAQ:ESGR

ESGR Rankings

#1846 Ranked by Market Cap
N/A Ranked by Dividends

ESGR Latest News

Jul 2, 2025
Sixth Street Completes Acquisition of Enstar
May 5, 2025
Enstar Group Limited Announces Quarterly Preference Share Dividends
Apr 24, 2025
AXIS Completes Previously Announced Transaction With Enstar
Mar 17, 2025
Enstar Group Limited Announces Expiration and Results of Cash Tender Offer For Junior Subordinated Notes Due 2040
Mar 12, 2025
Enstar Group Limited Announces Pricing of $350 Million of 7.500% Fixed-Rate Reset Junior Subordinated Notes Due 2045

ESGR Latest SEC Filings

Jul 2, 2025
[SCHEDULE 13D/A] Enstar Group SEC Filing
Jul 2, 2025
[POS AM] Enstar Group SEC Filing
Jul 2, 2025
[POSASR] Enstar Group SEC Filing
Jul 2, 2025
[POSASR] Enstar Group SEC Filing
Jul 2, 2025
[POS AM] Enstar Group SEC Filing

ESGR Stock Data

5.01B
11.78M
10.79%
84.93%
1.11%
Insurance - Diversified
Fire, Marine & Casualty Insurance
Bermuda
HAMILTON